

Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Ongoing Global Clinical Trials Analysis and Outlook

<https://marketpublishers.com/r/H025A40CF61EN.html>

Date: June 2018

Pages: 41

Price: US\$ 700.00 (Single User License)

ID: H025A40CF61EN

Abstracts

Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer ongoing clinical trials report from VPA Research provides comprehensive analysis and trends in global Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer disease clinical trials. The research work analyzes the ongoing Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trials.

Scope of the Report-

Ongoing Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trials across regions

Trial information by Phase and Subjects recruited

Trial information by status, type, sponsor type

Drugs used for treatment of Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer

Both observational and interventional trials analyzed

Leading companies and universities participating in Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trials

Reasons to Buy

Track competition and design competitive advantages

Identify right partners to associate with for further research

Evaluate potential opportunities available in further clinical trials of the disease

Formulate business development strategies through success rates of clinical trials

Identify quick markets for recruiting subjects based on trials count by each market

Contents

1 TABLE OF CONTENTS

- 1.1 List of Figures
- 1.2 List of Tables

2 KEY FINDINGS, 2018

- 2.1 Snapshot
- 2.2 Overview of Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials

3 CLINICAL TRIALS TRENDS TO 2022

- 3.1 Ongoing Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Phase
- 3.2 Ongoing Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Type
- 3.3 Ongoing Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Recruitment Status

4 COUNTRY LEVEL ANALYSIS

- 4.1 Region wise Ongoing Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials
- 4.2 Top 10 Countries conducting Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials
- 4.3 Trials in Emerging and Developing Economies

5 COMPANY LEVEL ANALYSIS

- 5.1 Ongoing Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Sponsor Type
- 5.2 Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Subjects by Sponsor Type
- 5.3 Subjects Recruited by Leading Sponsors

6 ENROLMENT TRENDS TO 2022

Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Ongoing Global Clinical Trials...

6.1 Subjects Recruited for Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by year

6.2 Subjects Recruited for Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Phase

6.3 Subjects Recruited for Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Trial Type

6.4 Subjects Recruited for Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Recruitment Status

7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS

7.1 Ongoing Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase

7.2 Ongoing Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase

7.3 Ongoing Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase

7.4 Ongoing Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase

8 APPENDIX

8.1 Abbreviations and Definitions

8.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Country

Figure 2: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Phase of Development, 2018

Figure 3: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Status, 2018

Figure 4: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Type, 2018

Figure 5: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials Split by Region, 2000-2018

Figure 6: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Type of Economy, 2018

Figure 7: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Phase, 2018

Figure 8: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Trial Type, 2018

Figure 9: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Recruitment Status, 2018

Figure 10: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Sponsor Type, 2018

Figure 11: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Type of Sponsors

Figure 12: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Leading Sponsors

List Of Tables

LIST OF TABLES

Table 1: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Sponsor Type, 2018

Table 2: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Economy Type, 2018

Table 3: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Region, 2018

Table 4: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trial Participations of Top 10 Countries, 2018

Table 5: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials in Emerging and Developing Economies, 2018

Table 6: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company

Table 7: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company

Table 8: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company

Table 9: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company

I would like to order

Product name: Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Ongoing Global Clinical Trials Analysis and Outlook

Product link: <https://marketpublishers.com/r/H025A40CF61EN.html>

Price: US\$ 700.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H025A40CF61EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

